跳至主要内容
临床试验/NCT03158480
NCT03158480Unknown不适用

Safety and Efficacy of Immune Therapy for Condyloma

Shenzhen Second People's Hospital1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2017年6月25日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
80
试验地点
1
主要终点
Condylomata Acuminata recurrence rate

研究概览

简要总结

Cytokine-induced killer (CIK) cells will be co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to Condylomata Acuminata patients using interferon, whose recurrence rate and total cost will be compared to Condylomata Acuminata patients only use interferon.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • All patients have typical clinical characters of condyloma, positive for HPV-DNA test; All patients have been treated for cryotherapy or laser plus interferon for over half a year without completely recovery. All patients or their family will sign informed consent and approved by Ethics Committee of Shenzhen Second People's Hospital -

排除标准

  • pregnant, blood disease, contraindication for immune therapy, allergic to interferon

结局指标

主要结局

Condylomata Acuminata recurrence rate

时间窗: 6 months

Condylomata Acuminata recurrence rate in 6 months after treatment

次要结局

  • side effect(6 months)
  • skin tissue HPV gene(6 months)

研究者

发起方
Shenzhen Second People's Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Safety and Efficacy of Immune Therapy for Condyloma | 临床试验